Hülsmeier Andreas J, Paesold-Burda Patricie, Hennet Thierry
Institute of Physiology and Center for Integrative Human Physiology, University of Zürich, Winterthurerstrasse 190, 8057 Zürich, Switzerland.
Mol Cell Proteomics. 2007 Dec;6(12):2132-8. doi: 10.1074/mcp.M700361-MCP200. Epub 2007 Sep 6.
Congenital disorders of glycosylation (CDGs) are a family of N-linked glycosylation defects associated with severe clinical manifestations. In CDG type-I, deficiency of lipid-linked oligosaccharide assembly leads to the underoccupancy of N-glycosylation sites on glycoproteins. Although the level of residual glycosylation activity is known to correlate with the clinical phenotype linked to individual CDG mutations, it is not known whether the degree of N-glycosylation site occupancy by itself correlates with the severity of the disease. To quantify the extent of underglycosylation in healthy control and in CDG samples, we developed a quantitative method of N-glycosylation site occupancy based on multiple reaction monitoring LC-MS/MS. Using isotopically labeled standard peptides, we directly quantified the level of N-glycosylation site occupancy on selected serum proteins. In healthy control samples, we determined 98-100% occupancy for all N-glycosylation sites of transferrin and alpha(1)-antitrypsin. In CDG type-I samples, we observed a reduction in N-glycosylation site occupancy that correlated with the severity of the disease. In addition, we noticed a selective underglycosylation of N-glycosylation sites, indicating preferential glycosylation of acceptor sequons of a given glycoprotein. In transferrin, a preferred occupancy for the first N-glycosylation site was observed, and a decreasing preference for the first, third, and second N-glycosylation sites was observed in alpha(1)-antitrypsin. This multiple reaction monitoring LC-MS/MS method can be extended to multiple glycoproteins, thereby enabling a glycoproteomics survey of N-glycosylation site occupancies in biological samples.
先天性糖基化障碍(CDG)是一类与严重临床表现相关的N-连接糖基化缺陷疾病。在I型CDG中,脂连接寡糖组装缺陷导致糖蛋白上N-糖基化位点占用不足。虽然已知残余糖基化活性水平与个体CDG突变相关的临床表型相关,但尚不清楚N-糖基化位点的占用程度本身是否与疾病严重程度相关。为了量化健康对照和CDG样本中糖基化不足的程度,我们开发了一种基于多反应监测液相色谱-串联质谱的N-糖基化位点占用定量方法。使用同位素标记的标准肽,我们直接定量了选定血清蛋白上N-糖基化位点的占用水平。在健康对照样本中,我们测定了转铁蛋白和α1-抗胰蛋白酶所有N-糖基化位点的占用率为98%-100%。在I型CDG样本中,我们观察到N-糖基化位点占用率降低,这与疾病严重程度相关。此外,我们注意到N-糖基化位点存在选择性糖基化不足,表明给定糖蛋白的受体序列存在优先糖基化。在转铁蛋白中,观察到第一个N-糖基化位点的优先占用,而在α1-抗胰蛋白酶中,观察到对第一、第三和第二个N-糖基化位点的优先占用降低。这种多反应监测液相色谱-串联质谱方法可以扩展到多种糖蛋白,从而能够对生物样本中的N-糖基化位点占用情况进行糖蛋白组学研究。